CNBC Europe highlighted GammaDelta Therapeutics in a recent report based on the interdisciplinary research activities undertaken at the Francis Crick Institute. Prof. Adrian Hayday, a scientific founder of GammaDelta Therapeutics, summarized the basic research undertaken within his laboratories, including those at the Francis Crick Institute, which contributed to the launch of the spin-out company GammaDelta Therapeutics. The report noted the successful $100m collaboration between GammaDelta Therapeutics and Takeda to support the development of novel immunotherapies.